HC Wainwright Issues Positive Estimate for ELTX Earnings

Elicio Therapeutics, Inc. (NASDAQ:ELTX) – Investment analysts at HC Wainwright raised their Q2 2026 EPS estimates for Elicio Therapeutics in a research note issued to investors on Monday, June 15th. HC Wainwright analyst R. Burns now forecasts that the company will earn ($0.45) per share for the quarter, up from their prior estimate of ($0.46). HC Wainwright has a “Buy” rating and a $23.00 price target on the stock. The consensus estimate for Elicio Therapeutics’ current full-year earnings is ($2.09) per share. HC Wainwright also issued estimates for Elicio Therapeutics’ Q3 2026 earnings at ($0.39) EPS, Q4 2026 earnings at ($0.39) EPS and FY2026 earnings at ($1.82) EPS.

Elicio Therapeutics (NASDAQ:ELTX) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.16).

Other analysts have also recently issued reports about the stock. Wall Street Zen cut shares of Elicio Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. B. Riley Financial started coverage on shares of Elicio Therapeutics in a report on Wednesday, June 10th. They issued a “buy” rating and a $27.00 target price on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Elicio Therapeutics in a research report on Friday, April 24th. LADENBURG THALM/SH SH initiated coverage on shares of Elicio Therapeutics in a report on Wednesday, April 15th. They set a “buy” rating and a $20.00 price target for the company. Finally, Rodman & Renshaw reaffirmed a “buy” rating on shares of Elicio Therapeutics in a research report on Monday. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $21.75.

Elicio Therapeutics Stock Down 32.4%

Shares of Elicio Therapeutics stock opened at $2.76 on Wednesday. Elicio Therapeutics has a 12-month low of $2.66 and a 12-month high of $16.00. The company has a quick ratio of 2.24, a current ratio of 2.24 and a debt-to-equity ratio of 5.75. The stock has a 50 day moving average price of $11.08 and a two-hundred day moving average price of $9.88. The stock has a market capitalization of $52.69 million, a P/E ratio of -1.15 and a beta of 1.13.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Bank of America Corp DE lifted its stake in shares of Elicio Therapeutics by 186.8% in the third quarter. Bank of America Corp DE now owns 3,585 shares of the company’s stock valued at $39,000 after buying an additional 2,335 shares during the period. Geode Capital Management LLC increased its stake in Elicio Therapeutics by 2.2% during the fourth quarter. Geode Capital Management LLC now owns 132,518 shares of the company’s stock valued at $1,055,000 after acquiring an additional 2,832 shares during the period. Raymond James Financial Inc. acquired a new position in Elicio Therapeutics in the 2nd quarter valued at approximately $46,000. State Street Corp raised its holdings in Elicio Therapeutics by 20.9% in the 4th quarter. State Street Corp now owns 46,300 shares of the company’s stock valued at $369,000 after acquiring an additional 8,000 shares in the last quarter. Finally, Summit Financial LLC acquired a new stake in shares of Elicio Therapeutics during the 4th quarter worth approximately $80,000. Institutional investors and hedge funds own 35.03% of the company’s stock.

Elicio Therapeutics News Roundup

Here are the key news stories impacting Elicio Therapeutics this week:

• Positive Sentiment: HC Wainwright reportedly raised its price target and reiterated a buy rating, suggesting some analysts still see upside if the development strategy improves. Analyst price target update
• Neutral Sentiment: JonesTrading reaffirmed a hold rating, indicating a wait-and-see stance after the clinical update. JonesTrading rating reaffirmed
• Neutral Sentiment: The company also outlined a refined Phase 3 development strategy, but that longer-term plan has been overshadowed by the Phase 2 miss. Phase 2 results and Phase 3 strategy
• Negative Sentiment: The main catalyst is the failed AMPLIFY-7P trial endpoint, which directly undermines the investment case for ELI-002 7P and triggered a sharp selloff. Reuters report on trial miss
• Negative Sentiment: Law firms have already announced investigations into whether Elicio properly disclosed the trial setback, adding litigation risk and more pressure on the shares. Investigation announcement

About Elicio Therapeutics

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.